Nuvation Bio (NUVB) Accounts Payables (2020 - 2026)

Nuvation Bio (NUVB) has reported Accounts Payables for 7 consecutive years, with $22.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accounts Payables rose 112.92% year-over-year to $22.4 million; the TTM figure through Mar 2026 stood at $22.4 million (up 112.92% YoY), while the FY2025 annual figure was $9.5 million, up 49.32% from the prior year.
• Accounts Payables improved to $22.4 million in Q1 2026 per NUVB's latest filing, from $9.5 million in the prior quarter.
• Across five years, Accounts Payables topped out at $22.4 million in Q1 2026 and bottomed at $2.1 million in Q4 2022.
• Historically, Accounts Payables has averaged $8.5 million across 5 years, with a median of $6.3 million in 2024.
• Annual changes were most pronounced in 2023 — Accounts Payables slumped 79.75% — and 2024, when it jumped 421.7%.
• Nuvation Bio's Accounts Payables stood at $2.1 million in 2022, then advanced by 3.27% to $2.2 million in 2023, then surged by 187.37% to $6.3 million in 2024, then surged by 49.32% to $9.5 million in 2025, then soared by 136.68% to $22.4 million in 2026.
• Business Quant data shows NUVB's Accounts Payables at $22.4 million in Q1 2026, $9.5 million in Q4 2025, and $15.4 million in Q3 2025.